Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction
Mira Pharmaceuticals Inc. has announced the results of a preclinical study involving SKNY-1, an oral drug candidate under a definitive agreement for acquisition. The study, conducted using a zebrafish model, examined the drug's effects on anxiety-related behavior linked to the Cannabinoid 1 receptor (CB1). SKNY-1 demonstrated a reversal of anxiety-induced behavior caused by a CB1 activator, differentiating it from previous CB1-targeting drugs discontinued due to central nervous system side effects. The drug's distinct pharmacological profile includes biased CB1 antagonism, partial CB2 receptor activation, and mild MAO-B inhibition. Mira Pharmaceuticals is preparing for shareholder approval for the acquisition of SKNY Pharmaceuticals, Inc., with plans to initiate Investigational New Drug $(IND.AU)$-enabling studies for SKNY-1 pending approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-018595), on July 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.